Actelion Pharmaceuticals Ltd

Type: Company
Name: Actelion Pharmaceuticals Ltd (Actelion Ltd)
Nationality: Switzerland
Web Address: http://www.actelion.com/
Fact Sheet: Fact Sheet for Actelion Ltd
First reported Sep 23 2014 - Updated Sep 24 2014 - 1 reports

AstraZeneca, Shire dive as U.S. tax move punctures deal hopes

LONDON - Shares in drugmakers AstraZeneca and Shire fell sharply on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad.The move could jeopardize an agreed deal ... [Published Today Online - Sep 23 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 3 reports

Inversion deal crackdown hits stocks

A handful of companies that investors once viewed as ripe for takeover by US rivals isn't looking so attractive, after the White House unveiled a sweeping effort at cracking down on the tax benefits of cross-Atlantic mergers.The Obama administration moved ... [Published Business Spectator - Sep 23 2014]
Entities: AbbVie Inc, Inversion, Taxes
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Swiss Stocks Fall Further From 6-Year Highs

Swiss stocks edged down for a second day in a row Tuesday, although losses were more pronounced in other major European markets.The Swiss Market Index slipped 0.61 percent to 8,763.80 at last check, moving further from 6-year highs seen earlier this month. ... [Published RTTNews.com - Sep 23 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Tax-deal crackdown's victims, say analysts? Mylan and Abbott, not Pfizer and AZ

Pfizer and AstraZeneca, AbbVie and Shire, Hospira and Danone. Those are a few of the merger pairs--actual or potential--that stand to lose from U.S. Treasury Secretary Jack Lew's new tax-inversion-fighting rules. Just take a look at AstraZeneca and Shire's ... [Published FiercePharma - Sep 23 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 2 reports

UPDATE 1-AstraZeneca, Shire fall as U.S. tax move punctures deal hopes

* U.S. moves against tax-avoidance 'inversion' deals* May deter Pfizer from returning to bid for AstraZeneca* Seen as threat to Shire's agreed sale to AbbVie* Smith & Nephew, Actelion also down on fading bid hopes(Adds analyst comments, details)LONDON, ... [Published CNBC - Sep 23 2014]
First reported Sep 22 2014 - Updated Sep 22 2014 - 1 reports

Portfolio Update

Regulatory Story Company TIDM IBT Headline Released 10:14 22-Sep-2014 Number 2392S10 RNS Number : 2392S 22 September 2014  INTERNATIONAL BIOTECHNOLOGY TRUST PLC Portfolio Update as at 31 August 2014 Net Assets £215m Net Assets per share 396p Share price ... [Published London Stock Exchange - Sep 22 2014]
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Swiss Stocks Little Changed After Scotland Rejects Independence

Swiss stocks inched a bit higher Friday, staying near record highs amid little reaction to Scotland spurning independence from the U.K.The Swiss Market Index rose 0.11 percent to 8,840.17, led by gains among Actelion and Swiss Re.Cement maker Holcim shares ... [Published RTTNews.com - Sep 19 2014]
Entities: Scotland, Holcim Ltd, Stocks
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Europe's Largest Biopharmaceutical Company Takes Big Leap Into Procurement-Powered Business Performance With Zycus

BASEL, SWITZERLAND--(BUSINESS WIRE)--Zycus , a world leader in Procurement Technology solutions across the source-to-pay cycle, announced today that Actelion, Europe's largest biopharmaceutical company, will adopt its complete suite of procurement performance ... [Published Purchasing Network - Sep 19 2014]
First reported Sep 18 2014 - Updated Sep 18 2014 - 1 reports

European Slowdown Risk Spurs Surge in Swiss Stock Haven

Investors put off by slowing growthand lackluster yields in Europe are finding havens in companiesthat sell cancer drugs and baby food .They aren’t only safe, they’re Swiss, with investorspouring a record amount into an exchange-traded fund trackingthe ... [Published Bloomberg - Sep 18 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Patient-reported outcome tool for C. difficile -associated diarrhea accurately addressed patient experience

WASHINGTON, D.C. — Patients reported that a new patient-reported outcome assessment tool developed based on the FDA PRO Guidance for Industry was easy to understand and relevant to their experience of Clostridium difficile -related diarrhea symptoms, ... [Published Orthopedics Today - Sep 09 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

ACTELION : Europe's Largest Biopharmaceutical Company Takes Big Leap into Procurement-Powered Business Performance with Zycus

Headquartered in Allschwil/ Basel, Switzerland , Actelion has more than 30 operating affiliates around the world, including the United States , Canada , Brazil , Australia , Japan , Switzerland and a number of EU countries. In June 2013 Actelion began ... [Published 4 Traders - Sep 05 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 3 reports

Actelion Pharmaceuticals US, Inc. Release: Europe's Largest Biopharmaceutical Company Takes Big Leap into Procurement-Powered Business Performance With

BASEL, Switzerland--(BUSINESS WIRE)--Zycus, a world leader in Procurement Technology solutions across the source-to-pay cycle, announced today that Actelion, Europe's largest biopharmaceutical company, will adopt its complete suite of procurement performance ... [Published BioSpace - Sep 04 2014]

Quotes

"I think because of that uncertainty people wanted to wait and see how that was going to be resolved" Jason Kaplan, a tax attorney for the law firm Hogan Lovells, said
..."We continue to believe that Pfizer will re-engage with AstraZeneca," he wrote in a note to investors, "given the multiple strategic, cost and tax benefits that remain despite today's action."
"Inversion deals now are clearly going to be very difficult to pull off" Navid Malik, head of life sciences research at Cenkos Securities, said
"Shire has enough momentum in its business and a good enough pipeline that it would be attractive to AbbVie anyway" Malik argued. "The tax inversion was the icing on the cake."

More Content

All (98) | News (67) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (2) | Press Releases (1)
sort by: Date | Relevance
Crackdown on Corporate Inversion Applies Pressu... [Published Zolmax News - Sep 23 2014]
Inversion deal crackdown hits stocks [Published Business Spectator - Sep 23 2014]
Shares Of 'inversion' Candidates Slide On U.S. ... [Published Clusterstock - Sep 23 2014]
Swiss Stocks Fall Further From 6-Year Highs [Published RTTNews.com - Sep 23 2014]
Tax-deal crackdown's victims, say analysts? Myl... [Published FiercePharma - Sep 23 2014]
Tax inversion target companies hit by U.S. crac... [Published Fortune - Sep 23 2014]
AstraZeneca, Shire dive as U.S. tax move punctu... [Published Today Online - Sep 23 2014]
AstraZeneca, Shire Dive As U.S. Tax Move Punctu... [Published Clusterstock - Sep 23 2014]
Drug company shares pummeled by US tax moves [Published CNBC - Sep 23 2014]
UPDATE 1-AstraZeneca, Shire fall as U.S. tax mo... [Published CNBC - Sep 23 2014]
BUZZ-Shire, AstraZeneca bearing the brunt as ne... [Published London South East - Sep 23 2014]
Pulmonary Disease Under-recognized in HIV [Published American Journal of Public Health - Sep 22 2014]
EXCLUSIVE INTERVIEW: Novo Nordisk answer key qu... [Published Prlog - Sep 22 2014]
Portfolio Update [Published London Stock Exchange - Sep 22 2014]
Swiss Stocks Little Changed After Scotland Reje... [Published RTTNews.com - Sep 19 2014]
Europe's Largest Biopharmaceutical Company Take... [Published Purchasing Network - Sep 19 2014]
BioSpecifics Technologies : to Present at the 2... [Published 4 Traders - Sep 19 2014]
European Slowdown Risk Spurs Surge in Swiss Sto... [Published Bloomberg - Sep 18 2014]
New Technology Identifies Neurotropic Astrovirus [Published Diabetes Care - Sep 17 2014]
United Therapeutics Points to Pluristem's PLX-P... [Published BioMedReports - Sep 17 2014]
Study Dampens HOPE of HIV Organ Donations [Published General Medicine eJournal - Sep 15 2014]
Two Drugs Better Than 1 for Pulmonary Hypertension [Published American Journal of Public Health - Sep 15 2014]
Pharma deals during August 2014 [Published PMLive - Sep 11 2014]
Arena Pharmaceuticals - A Biotech Value Investment [Published Seeking Alpha - Sep 10 2014]
Ambrisentan/tadalafil combo could be PAH standa... [Published Pharma Times - Sep 10 2014]
Patient-reported outcome tool for C. difficile ... [Published Orthopedics Today - Sep 09 2014]
Career Moves: Intarcia Therapeutics Appoints Su... [Published India-West - Sep 05 2014]
ACTELION : Europe's Largest Biopharmaceutical C... [Published 4 Traders - Sep 05 2014]
Actelion Pharmaceuticals US, Inc. Release: Euro... [Published BioSpace - Sep 04 2014]
Europe's Largest Biopharmaceutical Company Take... [Published Street Sweeper - Sep 04 2014]
1 2 3 4
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Shares Of 'inversion' Candidates Slide On U.S. ... [Published Clusterstock - Sep 23 2014]
By Ben Hirschler and Dan Burns LONDON/NEW YORK (Reuters) - The U.S. Treasury's move to curb deals that allow U.S. companies to escape high taxes at home wiped a combined $12.3 billion off the shares of nearly a dozen companies on both sides of the ...
AstraZeneca, Shire Dive As U.S. Tax Move Punctu... [Published Clusterstock - Sep 23 2014]
By Ben Hirschler LONDON (Reuters) - Shares in drugmakers AstraZeneca and Shire fell sharply on Tuesday after the U.S. Treasury took steps to curb "inversion" deals that allow companies to escape high U.S. taxes by reincorporating abroad. The move ...
Research and Markets: Global Lysosomal Storage ... [Published Business Wire Health News - Aug 21 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5f7fvn/global_lysosomal) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The Global Lysosomal Storage ...
Global Lysosomal Storage Diseases Market 2014-2... [Published PR Newswire: General Business - Aug 18 2014]
DUBLIN, Aug. 18, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering. The term lysosomal storage diseases refers to a group of rare inherited disorders ...
Stop Abusing the Loophole! [Published The Big Red Biotech Blog - Aug 07 2014]
The US Treasury and lawmakers say they will push ahead with their attempts to prevent further tax inversion deals from proceeding --- and they will push to make this legislation retroactive to take away rewards accomplished deals may have already gleaned. ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
PatientsLikeMe and Actelion to Develop New Pati... [Published PatientsLikeMe Press Release - Aug 05 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.